• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2013 Product Image

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2013

  • Published: March 2013
  • 53 pages
  • Global Markets Direct

Meningococcemia (Meningococcal Infections) – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections). Meningococcemia (Meningococcal Infections) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Meningococcemia (Meningococcal Infections) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Meningococcemia (Meningococcal Infections) 8
Meningococcemia (Meningococcal Infections) Therapeutics under Development by Companies 10
Meningococcemia (Meningococcal Infections) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Meningococcemia (Meningococcal Infections) Therapeutics – Products under Development by Companies 16
Meningococcemia (Meningococcal Infections) Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Meningococcemia (Meningococcal Infections) Therapeutics Development 18
GlaxoSmithKline plc 18
Pfizer Inc. 19
Panacea Biotec Limited 20
Serum Institute of India Limited 21
Meningococcemia (Meningococcal Infections) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Meninge ACYW Conjugate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MnB rLP2086 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PsA-TT - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GSK-134612 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Haemophilus influenzae type b and meningococcal serogroup C (vaccine) + Priorix + Hiberix + Meningitec - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Conjugated Meningococcal C Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rLP2086 + MCV4 + Tdap - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MCV4 + Tdap - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rLP-2086 + Gardasil - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Meningococcal Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Kingella Kingae Outer Membrane Vesicles Based Vaccines - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Meningococcal Group B Recombinant Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Meningococcemia (Meningococcal Infections) Therapeutics – Drug Profile Updates 48
Meningococcemia (Meningococcal Infections) Therapeutics - Dormant Products 49
Meningococcemia (Meningococcal Infections) – Product Development Milestones 50
Featured News & Press Releases 50
Nov 08, 2012: Sanofi Pasteur Announces Publication Of Pivotal Safety And Immunogenicity Data Of Menactra Vaccine For Infants And Toddlers 50
Apr 22, 2011: Sanofi Pasteur Announces FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication for Infants 50
Dec 23, 2010: Novartis Submits Meningococcal B Vaccine For Regulatory Review In Europe 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Number of Products Under Development for Meningococcemia (Meningococcal Infections), H1 2013 8
Products under Development for Meningococcemia (Meningococcal Infections) – Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 17
GlaxoSmithKline plc, H1 2013 18
Pfizer Inc., H1 2013 19
Panacea Biotec Limited, H1 2013 20
Serum Institute of India Limited, H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 27
Meningococcemia (Meningococcal Infections) Therapeutics – Drug Profile Updates 48
Meningococcemia (Meningococcal Infections) Therapeutics – Dormant Products 49

List of Figures
Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2013 8
Products under Development for Meningococcemia (Meningococcal Infections) – Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Route of Administration, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Molecule Type, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 27

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos